论文部分内容阅读
目的对他汀类药物在早发冠心病急性心肌梗死患者治疗中的临床效果进行观察。方法 60例早发冠心病急性心肌梗死患者,随机分为对照组和观察组,各30例。其中对照组患者实施阿托伐他汀治疗,观察组患者实施瑞舒伐他汀治疗,对比两组患者临床疗效。结果观察组患者治疗后血清总胆固醇(TC)为(3.0±0.7)mmol/L、低密度脂蛋白胆固醇(LDL-C)为(1.5±0.4)mmol/L、超敏C反应蛋白(hs-CRP)为(1.9±0.6)mg/L,低于对照组患者的(3.4±0.7)mmol/L、(2.0±0.7)mmol/L、(2.4±0.6)mg/L,差异有统计学意义(P<0.05)。两组患者的甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、左室射血分数(LVEF)、血流介导的内皮舒张功能(FMD)、血运重建率、病情复发率及死亡率比较,差异均无统计学意义(P>0.05)。结论早发冠心病急性心肌梗死患者治疗中瑞舒伐他汀治疗效果优于阿托伐他汀,临床效果显著,值得推广应用。
Objective To observe the clinical effect of statins in the treatment of patients with premature coronary heart disease with acute myocardial infarction. Methods Sixty patients with early-onset coronary heart disease with acute myocardial infarction were randomly divided into control group and observation group, with 30 cases in each group. Patients in the control group were treated with atorvastatin, and patients in the observation group were given rosuvastatin. The clinical efficacy was compared between the two groups. Results After treatment, the total cholesterol (TC) in the observation group was (3.0 ± 0.7) mmol / L, the LDL-C level was 1.5 ± 0.4 mmol / L and the hs- CRP was (1.9 ± 0.6) mg / L, which was significantly lower than that of the control group (3.4 ± 0.7 mmol / L, (2.0 ± 0.7) mmol / L and (P <0.05). Two groups of patients with triglyceride (TG), high density lipoprotein cholesterol (HDL-C), left ventricular ejection fraction (LVEF), blood flow mediated endothelial function (FMD), revascularization rate, relapse There was no significant difference in rates and mortality (P> 0.05). Conclusion The effect of rosuvastatin on early-onset coronary heart disease in patients with acute myocardial infarction is better than that of atorvastatin, and the clinical effect is significant. It is worth popularizing and applying.